MPM Capital said Wednesday it named Dr. Patrick A. Baeuerle a Managing Director effective April 1. Baeuerle most recently was Vice President, Research, and General Manager, Amgen Research (Munich) GmbH.
BOSTON–(BUSINESS WIRE)–MPM Capital today announces the appointment of Dr. Patrick A. Baeuerle as Managing Director, effective April 1, 2015. A renowned pioneer in the development of T-cell based human therapies for cancer and a proven drug-developer, Dr. Baeuerle extends MPM expertise in assessing the science behind breakthrough discoveries and drugs that can lead to new treatments and cures.
“We are thrilled Dr. Baeuerle has selected MPM Capital as he brings unique perspective as a ground-breaking and highly-cited biomedical scientist in the exploding area of T-cell immunology, as well as practical experience in the drug discovery and development process,” said Ansbert K. Gadicke, MPM Capital Managing Director and co-founder.
Dr. Baeuerle is responsible for the development of BiTE antibody BLYNCYTO (blinatumomab; AMG 103) which was approved in under three months by the US FDA for therapy of relapsed/refractory ALL (following breakthrough therapy designation and priority review). He spearheaded the industrial development of the BiTE technology, the industry-leading T-cell engaging antibody platform.
Most recently, he served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development, and served as site head. From 1998-2012, Dr. Baeuerle served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen.
Dr. Baeuerle earlier in his career was Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany. He also held a group leader position at the Gene Center in Martinsried, Germany, where he did seminal research on transcription factor NF-kappaB.
Dr. Baeuerle was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of several awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology.
About MPM Capital — MPM Capital (http://www.mpmcapital.com) is a global leader in early-stage life sciences venture investing with a track record of success in building world-class companies around transformational treatments and cures. With its deep experience, dedicated team of operating executives and distinguished MSAB, MPM Capital is powering medical breakthroughs that change lives.